Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers – The filing reports executive leadership or board composition changes and/or modifications to officer compensation arrangements as of January 10, 2026 Item 8.01: Regulation FD Disclosure – The company is disclosing material information…

Our analysis rates this filing BULLISH. This 8-K filing presents a routine and constructive corporate governance action with no material risks or adverse developments. The board expansion with Zurbay's appointment is a positive signal: his extensive healthcare finance background, prior Patterson…

Concern level: LOW (1.8/10). Key factors: No material risks identified in filing; No negative events, litigation, regulatory issues, or adverse developments disclosed; No financial guidance provided (typical for governance-only 8-K).

Notable risk changes: Board expansion from 10 to 11 directors with appointment of Donald Zurbay, former Patterson Companies CEO/CFO with deep dental industry experience; Formation of Growth and Value Creation Committee co-chaired by Chairman Lucier and CEO Scavilla to oversee Return-to-Growth action plan execution; Strategic governance enhancement signaling board confidence in management's growth strategy and…

The model predicts XRAY will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.